MetaCap

IDEAYA Biosciences (IDYA) vs SELLAS Life Sciences Group (SLS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SELLAS Life Sciences Group (SLS) has outperformed IDEAYA Biosciences (IDYA) over the past year, gaining 792.8% versus a loss of 24.8%. Over five years, SLS leads with a +94.0% price change compared with +7.3% for IDYA. SELLAS Life Sciences Group is the larger company by market cap ($2.78 billion vs $2.47 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IDYA-24.80%SLS+792.81%
+1210%+563%-84%
Nov 21, 20251 yearNov 20, 2026
IDYA+10.08%SLS+94.86%
+131%+14%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IDYA versus SLS key metrics
MetricIDYASLS
Share price$25.56$13.66
Market cap$2.47B$2.78B
1-day change-2.33%-8.08%
YTD return-26.06%+262.33%
1-year return-24.80%+792.81%
5-year return+7.35%+94.03%
EPS (TTM)$-4.50$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$218.71M—
Revenue growth (YoY)+3024.43%—
Net income (latest FY)$-113.70M$-26.86M
Operating margin-72.84%—
Net margin-51.99%—
52-week high$42.68$24.89
52-week low$25.46$1.39
Distance from 52-week high-40.11%-45.12%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+98.32%+137.92%
Average volume933.58K9.64M
Shares outstanding96.69M203.86M
Employees14513
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SLS has outperformed IDYA by 817.6 percentage points over the past year.

About IDEAYA Biosciences

IDYA stock →

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.

Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees

About SELLAS Life Sciences Group

SLS stock →

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

IDYA vs SLS FAQ

Which is bigger, IDEAYA Biosciences or SELLAS Life Sciences Group?

SELLAS Life Sciences Group (SLS) is larger, with a market capitalization of $2.78B compared with $2.47B for IDEAYA Biosciences (IDYA).

Which stock has performed better over the past year, IDYA or SLS?

SLS returned +792.81% over the past 12 months, compared with -24.80% for IDYA (price return, excluding dividends). Past performance does not predict future results.

Are IDEAYA Biosciences and SELLAS Life Sciences Group in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons